Cargando…

Non-cancer clinical trials start-up metrics at an academic medical center: Implications for advancing research

The primary goal for any clinical trial after it receives a funding notification is to receive regulatory approval and initiate the trial for recruitment. Every trial must go through documentation and regulatory process before it can start recruiting participants and collecting data; this initial pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Cernik, Colin, Shergina, Elena, Thompson, Jeffrey, Blackwell, Karen, Stephens, Kyle, Kimminau, Kim S., Wick, Jo, Mayo, Matthew S., Gajewski, Byron, He, Jianghua, Mudaranthakam, Dinesh Pal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121646/
https://www.ncbi.nlm.nih.gov/pubmed/34027224
http://dx.doi.org/10.1016/j.conctc.2021.100774
_version_ 1783692405292138496
author Cernik, Colin
Shergina, Elena
Thompson, Jeffrey
Blackwell, Karen
Stephens, Kyle
Kimminau, Kim S.
Wick, Jo
Mayo, Matthew S.
Gajewski, Byron
He, Jianghua
Mudaranthakam, Dinesh Pal
author_facet Cernik, Colin
Shergina, Elena
Thompson, Jeffrey
Blackwell, Karen
Stephens, Kyle
Kimminau, Kim S.
Wick, Jo
Mayo, Matthew S.
Gajewski, Byron
He, Jianghua
Mudaranthakam, Dinesh Pal
author_sort Cernik, Colin
collection PubMed
description The primary goal for any clinical trial after it receives a funding notification is to receive regulatory approval and initiate the trial for recruitment. Every trial must go through documentation and regulatory process before it can start recruiting participants and collecting data; this initial process of review and approval is known as the study start-up process (SSU). We evaluated the average time taken for studies to receive approvals. Using data from clinical trials conducted at the University of Kansas Medical Center, various times to reach the start of the study were calculated based on the dates of individual study. The results of this analysis showed that chart review studies and investigator-initiated trials had a shorter time to activation than other types of studies. Additionally, single-center studies had a shorter activation time than multi-center studies. The analysis also demonstrated that the overall processing time consistently had been reduced over time.
format Online
Article
Text
id pubmed-8121646
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-81216462021-05-20 Non-cancer clinical trials start-up metrics at an academic medical center: Implications for advancing research Cernik, Colin Shergina, Elena Thompson, Jeffrey Blackwell, Karen Stephens, Kyle Kimminau, Kim S. Wick, Jo Mayo, Matthew S. Gajewski, Byron He, Jianghua Mudaranthakam, Dinesh Pal Contemp Clin Trials Commun Article The primary goal for any clinical trial after it receives a funding notification is to receive regulatory approval and initiate the trial for recruitment. Every trial must go through documentation and regulatory process before it can start recruiting participants and collecting data; this initial process of review and approval is known as the study start-up process (SSU). We evaluated the average time taken for studies to receive approvals. Using data from clinical trials conducted at the University of Kansas Medical Center, various times to reach the start of the study were calculated based on the dates of individual study. The results of this analysis showed that chart review studies and investigator-initiated trials had a shorter time to activation than other types of studies. Additionally, single-center studies had a shorter activation time than multi-center studies. The analysis also demonstrated that the overall processing time consistently had been reduced over time. Elsevier 2021-05-04 /pmc/articles/PMC8121646/ /pubmed/34027224 http://dx.doi.org/10.1016/j.conctc.2021.100774 Text en © 2021 The Authors. Published by Elsevier Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Cernik, Colin
Shergina, Elena
Thompson, Jeffrey
Blackwell, Karen
Stephens, Kyle
Kimminau, Kim S.
Wick, Jo
Mayo, Matthew S.
Gajewski, Byron
He, Jianghua
Mudaranthakam, Dinesh Pal
Non-cancer clinical trials start-up metrics at an academic medical center: Implications for advancing research
title Non-cancer clinical trials start-up metrics at an academic medical center: Implications for advancing research
title_full Non-cancer clinical trials start-up metrics at an academic medical center: Implications for advancing research
title_fullStr Non-cancer clinical trials start-up metrics at an academic medical center: Implications for advancing research
title_full_unstemmed Non-cancer clinical trials start-up metrics at an academic medical center: Implications for advancing research
title_short Non-cancer clinical trials start-up metrics at an academic medical center: Implications for advancing research
title_sort non-cancer clinical trials start-up metrics at an academic medical center: implications for advancing research
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8121646/
https://www.ncbi.nlm.nih.gov/pubmed/34027224
http://dx.doi.org/10.1016/j.conctc.2021.100774
work_keys_str_mv AT cernikcolin noncancerclinicaltrialsstartupmetricsatanacademicmedicalcenterimplicationsforadvancingresearch
AT sherginaelena noncancerclinicaltrialsstartupmetricsatanacademicmedicalcenterimplicationsforadvancingresearch
AT thompsonjeffrey noncancerclinicaltrialsstartupmetricsatanacademicmedicalcenterimplicationsforadvancingresearch
AT blackwellkaren noncancerclinicaltrialsstartupmetricsatanacademicmedicalcenterimplicationsforadvancingresearch
AT stephenskyle noncancerclinicaltrialsstartupmetricsatanacademicmedicalcenterimplicationsforadvancingresearch
AT kimminaukims noncancerclinicaltrialsstartupmetricsatanacademicmedicalcenterimplicationsforadvancingresearch
AT wickjo noncancerclinicaltrialsstartupmetricsatanacademicmedicalcenterimplicationsforadvancingresearch
AT mayomatthews noncancerclinicaltrialsstartupmetricsatanacademicmedicalcenterimplicationsforadvancingresearch
AT gajewskibyron noncancerclinicaltrialsstartupmetricsatanacademicmedicalcenterimplicationsforadvancingresearch
AT hejianghua noncancerclinicaltrialsstartupmetricsatanacademicmedicalcenterimplicationsforadvancingresearch
AT mudaranthakamdineshpal noncancerclinicaltrialsstartupmetricsatanacademicmedicalcenterimplicationsforadvancingresearch